Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 8/20 | 0.34 |
| ▸ | CES1 | P23141 | 6/20 | 0.33 |
| ▸ | CES2 | O00748 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL457553 | 0.97 | FAAH (0.36) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28246387 | 0.93 | FAAH (0.31) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL60804 | 0.90 | FAAH (0.32) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL8181430 | 0.86 | DPP8 (0.32) | FAAH | |
| Trifluoroacetic Acid SCHEMBL6909668 | 0.80 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL27841664 | 0.80 | FAAH (0.42) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL31031817 | 0.80 | FAAH (0.42) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3794549 | 0.77 | FAAH (0.40) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL281599 | 0.77 | FAAH (0.40) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL15711042 | 0.77 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106046047-B | The method for preparing phosphorylation serine phosphonic acids analogies | 清华大学 | 2018-10-02 | — | — | CN | claimed |
| CN-106046047-B | The method for preparing phosphorylation serine phosphonic acids analogies | 清华大学 | 2018-10-02 | — | — | CN | disclosed |
| US-20170258711-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | NOVO NORDISK AS (DK) | 2017-09-14 | — | — | US | disclosed |
| US-20150265710-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | NOVO NORDISK A/S (DK) | 2015-09-24 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150093758-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | NATIONAL INSTITUTES OF HEALTH | 2015-04-02 | — | — | US | disclosed |
| US-8841083-B2 | PSA capture agents, compositions, methods and preparation thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120202219-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-09 | — | — | US | disclosed |
| US-7182945-B2 | Anti-inflammatory peptides derived from C-reactive protein | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-27 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-0996633-B1 | ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN | YEDA RES & DEV (IL) | 2004-03-17 | — | — | EP | disclosed |
| US-20030152564-A1 | Anti-inflammatory peptides derived from C-reactive protein | YEDA RESEARCH AND DEVELOPMENT CO., LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2003-08-14 | — | — | US | disclosed |
| US-6528618-B1 | Synthetic peptides; serine proteases; human leukocyte elastase; cathepsin G; chronic inflamation conditons; rheumatoid arthritis; pulmonary emphysema; cystic fibrosis; bronchitis; asthma | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2003-03-04 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020119917-A1 | ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2002-08-29 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0949508-A1 | Method, antigen complex and kit for diagnosing Lyme borreliosis | DAKO A/S (DK) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202219-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | KLK3, ACP3, SPAG5 | MEN1 2127/4885FAAH 3442/4885CES1 3319/4885 |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | MEN1 672/4885FAAH 2435/4885CES1 1874/4885 |
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | MEN1 1976/4885FAAH 3880/4885CES1 3379/4885 |
| US-20150265710-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | SLC27A1, SLC27A2, FABP2 | MEN1 4066/4885FAAH 83/4885CES1 2707/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | MEN1 3208/4885FAAH 3125/4885CES1 2595/4885 |
| US-20170258711-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | SLC27A1, SLC27A2, FABP2 | MEN1 4066/4885FAAH 83/4885CES1 2707/4885 |
| US-20150093758-A1 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF | KLK3, ACP3, SPAG5 | MEN1 2127/4885FAAH 3442/4885CES1 3319/4885 |
| US-20020119917-A1 | ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN | CTSE, CTSG, CTSL | MEN1 4648/4885FAAH 679/4885CES1 211/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | MEN1 4362/4885FAAH 1629/4885CES1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.